Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy as neoadjuvant therapy for locally advanced colorectal cancer
ChiCTR2400094505Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in colorectal cancer (CRC), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Pathologic complete response. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400094505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094505.